Literature DB >> 18757784

Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.

David J Greenblatt1, Lisa L von Moltke.   

Abstract

The role of gender on the disposition of drugs metabolized by cytochrome P4503A (CYP3A) remains controversial. Some sources suggest that CYP3A activity in women exceeds that in men, but evidence to support this position is inconsistent at best. We evaluated 38 data sets in which clearance of CYP3A substrate drugs was studied in healthy young male and young female subjects. None of these drugs was a substrate for transport by P-glycoprotein (P-gp). The overall mean (+/-SE) for the female/male ratio of weight-normalized clearance was 1.26 (+/-0.07) for parenteral dosage and 1.17 (+/-0.07) for oral dosage. Both ratios were significantly different (P < .05) from 1.0. For oral dosage studies, the female/male clearance ratio was unrelated to the drug's absolute oral bioavailability. Thus gender has a small and statistically significant, although most likely clinically unimportant, influence on CYP3A phenotype for substrates not transported by P-gp.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757784     DOI: 10.1177/0091270008323754

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  20 in total

Review 1.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

2.  Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals.

Authors:  Renli Teng; Patrick Mitchell; Kathleen Butler
Journal:  Eur J Clin Pharmacol       Date:  2012-02-25       Impact factor: 2.953

3.  Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.

Authors:  Kristine Hole; C Gjestad; K M Heitmann; T Haslemo; E Molden; S Bremer
Journal:  Eur J Clin Pharmacol       Date:  2016-12-14       Impact factor: 2.953

4.  Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in areas of malaria endemicity.

Authors:  Olumuyiwa N Adedeji; Oluseye O Bolaji; Catherine O Falade; Odusoga A Osonuga; Olusegun G Ademowo
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

5.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Authors:  David J Greenblatt; Diane E Peters; Lauren E Oleson; Jerold S Harmatz; Malcolm W MacNab; Noah Berkowitz; Miguel A Zinny; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

6.  Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Authors:  Michael H Court
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

7.  Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.

Authors:  Radmila Velickovic-Radovanovic; Momir Mikov; Aleksandra Catic-Djordjevic; Nikola Stefanovic; Branka Mitic; Goran Paunovic; Tatjana Cvetkovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-05       Impact factor: 2.441

8.  Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.

Authors:  David J Greenblatt; Jerold S Harmatz; Nikhilesh N Singh; Frank Steinberg; Thomas Roth; Stephen C Harris; Ram P Kapil
Journal:  Drugs Aging       Date:  2014-10       Impact factor: 3.923

Review 9.  The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.

Authors:  Shanna C Trenaman; Susan K Bowles; Melissa K Andrew; Kerry Goralski
Journal:  Pharmacol Res Perspect       Date:  2021-05

10.  Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus.

Authors:  H Naik; J Lu; C Cao; M Pfister; M Vakilynejad; E Leifke
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.